Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week Low – Should You Sell?

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reached a new 52-week low during trading on Tuesday . The stock traded as low as $35.53 and last traded at $36.21, with a volume of 958437 shares traded. The stock had previously closed at $37.82.

Analysts Set New Price Targets

Several research firms have weighed in on RARE. Wedbush reiterated a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Piper Sandler dropped their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday, March 17th. HC Wainwright reissued a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. upped their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Finally, Wells Fargo & Company raised their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Price Performance

The company has a market cap of $3.35 billion, a price-to-earnings ratio of -5.71 and a beta of 0.67. The firm has a fifty day simple moving average of $41.56 and a 200 day simple moving average of $46.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, insider John Richard Pinion sold 14,439 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. This trade represents a 11.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares of the company’s stock, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 493 shares during the period. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the third quarter worth $43,000. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical in the fourth quarter worth $35,000. Human Investing LLC bought a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at $42,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at $83,000. 97.67% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.